Expert in Metabolic Dysfunction-associated Steatohepatitis
Explore our industry-leading
translational models of
NASH/MASH & HCC
- Upcoming event : AASLD The Liver Meeting
- November 10-14, 2023
Gubra’s flagship model GAN DIO-MASH is top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our model portfolio and latest findings to ensure a successful preclinical study.
AASLD – The Liver Meeting
Download our posters
Meet Gubra at the AASLD – The Liver Meeting! Gubra is presenting 5 posters to discuss the clinical translatability of our flagship GAN DIO-MASH model, as well as other biopsy-confirmed preclinical models. Download the posters to learn more.
Standard Study Outlines
We are experts in bridging preclinical and clinical development.
Vice President, Scientific Sales
Michael’s primary focus is on MASH (NASH), MASH-HCC (NASH-HCC), IPF and IBD. Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.
Let’s meet at the EASL 2023
Hørsholm Kongevej 11B
+45 3152 2650